Analysts Set Fractyl Health, Inc. (NASDAQ:GUTS) Price Target at $5.40

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have received a consensus rating of “Hold” from the five analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $5.40.

Several analysts have recently weighed in on GUTS shares. Canaccord Genuity Group restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research note on Friday, December 19th. Morgan Stanley downgraded Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $8.00 to $2.00 in a report on Thursday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th.

Fractyl Health Stock Performance

GUTS stock opened at $0.42 on Thursday. The firm has a market cap of $56.87 million, a P/E ratio of -0.18 and a beta of 1.64. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $3.03. The stock has a 50-day simple moving average of $1.87 and a 200-day simple moving average of $1.47.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, equities research analysts predict that Fractyl Health will post -1.61 EPS for the current year.

Institutional Trading of Fractyl Health

Large investors have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd acquired a new stake in Fractyl Health in the 2nd quarter valued at approximately $26,000. Bank of America Corp DE lifted its holdings in shares of Fractyl Health by 23.5% in the third quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after buying an additional 16,856 shares during the period. Jane Street Group LLC bought a new position in Fractyl Health during the second quarter valued at about $31,000. FNY Investment Advisers LLC acquired a new position in Fractyl Health during the third quarter worth about $31,000. Finally, Scientech Research LLC bought a new stake in Fractyl Health in the third quarter worth about $49,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.